Der Browser den Sie verwenden ist sehr alt.

Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion.
Wir bitten um Ihr Verständnis.
Startseite > Forschung > Publikationen > Publikationen 2017

Publikationen 2017

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.
Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Volpe A, Ljungberg B, Bex A.
Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi: 10.1016/j.eururo.2017.11.016. [Epub ahead of print]
PMID: 29223605

Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer.
Kramer MW, Altieri V, Hurle R, Lusuardi L, Merseburger AS, Rassweiler J, Struck JP, Herrmann TRW.
Eur Urol Focus. 2017 Dec;3(6):567-576. doi: 10.1016/j.euf.2016.12.004. Epub 2017 Jan 11. Review.
PMID: 28753835

Retrospective Cost Analysis of a Single-Center Reusable Flexible Ureterorenoscopy Program: A Comparative Cost Simulation of Disposable fURS as an Alternative.
Ozimek T, Schneider MH, Hupe MC, Wiessmeyer JR, Cordes J, Chlosta PL, Merseburger AS, Kramer MW.
J Endourol. 2017 Dec;31(12):1226-1230. doi: 10.1089/end.2017.0427. Epub 2017 Nov 17.
PMID: 29073769

68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer.
von Klot CJ, Merseburger AS, Böker A, Schmuck S, Ross TL, Bengel FM, Kuczyk MA, Henkenberens C, Christiansen H, Wester HJ, Solass W, Lafos M, Derlin T.
Nucl Med Mol Imaging. 2017 Dec;51(4):314-322. doi: 10.1007/s13139-017-0476-7. Epub 2017 Mar 7.
PMID: 29242725

Rho GDP dissociation inhibitor-β in renal cell carcinoma.
von Klot CA, Dubrowinskaja N, Peters I, Hennenlotter J, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.
Oncol Lett. 2017 Dec;14(6):8190-8196. doi: 10.3892/ol.2017.7233. Epub 2017 Oct 20.
PMID: 29250194

Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets.
Morera DS, Hennig MS, Talukder A, Lokeshwar SD, Wang J, Garcia-Roig M, Ortiz N, Yates TJ, Lopez LE, Kallifatidis G, Kramer MW, Jordan AR, Merseburger AS, Manoharan M, Soloway MS, Terris MK, Lokeshwar VB.
Br J Cancer. 2017 Nov 7;117(10):1507-1517. doi: 10.1038/bjc.2017.318. Epub 2017 Oct 3.
PMID: 28972965

[Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)-study AP 93/16 of the AUO].
Rexer H, Graefen M, Merseburger A; AUO.
Urologe A. 2017 Nov;56(11):1471-1472. doi: 10.1007/s00120-017-0519-9. German. No abstract available.
PMID: 28980011

[Support of young urologists : The German Society of Residents in Urology sponsoring membership].
Nestler T, Salem J, Struck JP, Ralla B.
Urologe A. 2017 Nov;56(11):1473-1474. doi: 10.1007/s00120-017-0503-4. German. No abstract available.
PMID: 28980012

[Upgrade of the resident's job exchange platform].
Weber R, Cebulla A, Nachite-Berges S, Paffenholz P, Salem J, Ralla B, Uhthoff H, Schröder A, Struck JP.
Urologe A. 2017 Oct;56(10):1333-1334. doi: 10.1007/s00120-017-0502-5. German. No abstract available.
PMID: 28900656

[Work and training conditions of residents in urology in Germany : Results of a 2015 nationwide survey by the German Society of Residents in Urology].
Arnold H, Meyer CP, Salem J, Raspe M, Struck JP, Borgmann H.
Urologe A. 2017 Oct;56(10):1311-1319. doi: 10.1007/s00120-017-0495-0. German.
PMID: 28835996

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.
Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.
Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.
PMID: 29034236

Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
Jiang P, Krockenberger K, Vonthein R, Tereszczuk J, Schreiber A, Liebau S, Huttenlocher S, Imhoff D, Balermpas P, Keller C, Dellas K, Baumann R, Rödel C, Hildebrandt G, Jünemann KP, Merseburger AS, Katz A, Ziegler A, Blanck O, Dunst J.
Radiat Oncol. 2017 Aug 18;12(1):138. doi: 10.1186/s13014-017-0872-2.
PMID: 28821268

[En-bloc resection of bladder tumours (ERBT): current and future perspectives].
Struck JP, Kramer MW, Merseburger AS, Hartmann A, Herrmann TRW.
Aktuelle Urol. 2017 Aug;48(4):306-313. doi: 10.1055/s-0043-109819. Epub 2017 Jul 27. German.
PMID: 28750447

Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.
Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Staehler M, Volpe A, Powles T.
Eur Urol. 2017 May;71(5):719-722. doi: 10.1016/j.eururo.2016.11.034. Epub 2016 Dec 13.
PMID: 27986369

[Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]
Gilbert N, Merseburger AS, Kramer MW.
Urologe A. 2017 May;56(5):604-609. doi: 10.1007/s00120-017-0364-x. German.
PMID: 28314973

[The Lubeck medical consultation bag].
Hupe MC, Hennig MJP, Struck JP, Salem J, Merseburger AS, Kramer MW.
Urologe A. 2017 May;56(5):662-664. doi: 10.1007/s00120-017-0372-x. German. No abstract available.
PMID: 28289781

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.
Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A.
Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. eCollection 2017 Sep 19.
PMID: 29050215

Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer.
Jordan AR, Lokeshwar SD, Lopez LE, Hennig M, Chipollini J, Yates T, Hupe MC, Merseburger AS, Shiedlin A, Cerwinka WH, Liu K, Lokeshwar VB.
Oncotarget. 2017 Apr 11;8(15):24262-24274. doi: 10.18632/oncotarget.10529.
PMID: 27419371

Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer.
Haupt F, Berding G, Namazian A, Wilke F, Böker A, Merseburger A, Geworski L, Kuczyk MA, Bengel FM, Peters I.
Adv Ther. 2017 Apr;34(4):986-994. doi: 10.1007/s12325-017-0505-z. Epub 2017 Mar 7.
PMID: 28265811

Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer.
Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.
Clin Cancer Res. 2017 Apr 1;23(7):1829-1840. doi: 10.1158/1078-0432.CCR-16-0094. Epub 2016 Sep 27.
PMID: 27678455

Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
Cronauer MV, Merseburger AS, Hoda MR.
Eur Urol. 2017 Apr;71(4):e105-e106. doi: 10.1016/j.eururo.2016.09.021. Epub 2016 Sep 20. No abstract available.
PMID: 27663049

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM, Mukherjee SD, Zalewski P, Saad F, Jacobs C, Gleave M, de Bono JS.
Lancet Oncol. 2017 Apr;18(4):473-485. doi: 10.1016/S1470-2045(17)30168-7. Epub 2017 Mar 8.
PMID: 28283282

[Relaunch of the GeSRU website : Strategy, concept, and realization].
Ralla B, Arnold H, König J, Cebulla A, Nestler T, Struck J, Borgmann H, Salem J.
Urologe A. 2017 Apr;56(4):512-514. doi: 10.1007/s00120-017-0367-7. German. No abstract available.
PMID: 28293704

Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
Kovács G, Müller K, Soror T, Melchert C, Guo X, Jocham D, Merseburger A.
Brachytherapy. 2017 Mar - Apr;16(2):277-281. doi: 10.1016/j.brachy.2016.11.005. Epub 2016 Dec 7.
PMID: 27964906

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.
Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8. Review.
PMID: 27939075

Transurethral en bloc resection of nonmuscle invasive bladder cancer: trend or hype.
Herrmann TR, Wolters M, Kramer MW.
Curr Opin Urol. 2017 Mar;27(2):182-190. doi: 10.1097/MOU.0000000000000377. Review.
PMID: 28033148

C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer.
Azoitei A, Merseburger AS, Godau B, Hoda MR, Schmid E, Cronauer MV.
J Steroid Biochem Mol Biol. 2017 Feb;166:38-44. doi: 10.1016/j.jsbmb.2016.06.008. Epub 2016 Jun 21. Review.
PMID: 27345700

Stone/tissue differentiation for Holmium laser lithotripsy using autofluorescence: Clinical proof of concept study.
Lange B, Jocham D, Brinkmann R, Cordes J.
Lasers Surg Med. 2017 Apr;49(4):361-365. doi: 10.1002/lsm.22611. Epub 2016 Nov 12.
PMID: 27859390

[Focal dose escalation in the treatment of prostate cancer : Long-term results of HDR brachytherapy].
Cordes J, Broschk J, Sommerauer M, Jocham D, Merseburger AS, Melchert C, Kovács G.
Urologe A. 2017 Feb;56(2):157-166. doi: 10.1007/s00120-016-0164-8. German.
PMID: 27376359

[GeSRU e. V. - a success story].
Struck JP, Paffenholz P, Nachite S, Cebulla A, Ralla B, Salem J.
Urologe A. 2017 Feb;56(2):245-246. doi: 10.1007/s00120-016-0306-z. German. No abstract available.
PMID: 28093612

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.
Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.
PMID: 27974704

True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC).
Böker A, Kuczyk MA, Kramer MW, Merseburger AS, Krüger K, Imkamp F, von Klot CA.
Adv Ther. 2017 Jan;34(1):171-179. doi: 10.1007/s12325-016-0450-2. Epub 2016 Nov 26.
PMID: 27889882

[Twitter activity at the German Society of Urology congress #DGU16].
Beck A, Cebulla A, Salem J, Struck JP, Borgmann H.
Urologe A. 2017 Jan;56(1):77-79. doi: 10.1007/s00120-016-0285-0. German. No abstract available.
PMID: 27921125

Editorial comment.
Lotan Y, Merseburger AS.
Curr Opin Urol. 2017 Jan;27(1):34. No abstract available.
PMID: 27902674

Minimally invasive approaches to adrenal tumors: an up-to-date summary including patient position and port placement of laparoscopic, retroperitoneoscopic, robot-assisted, and single-site adrenalectomy.
Hupe MC, Imkamp F, Merseburger AS.
Curr Opin Urol. 2017 Jan;27(1):56-61. Review.
PMID: 27533502

Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
Hoda MR, Kramer MW, Merseburger AS, Cronauer MV.
Expert Opin Pharmacother. 2017 Jan;18(1):105-113. doi: 10.1080/14656566.2016.1258058. Epub 2016 Nov 28. Review.
PMID: 27826989

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy.
von Klot CA, Kuczyk MA, Boeker A, Reuter C, Imkamp F, Herrmann TR, Tezval H, Kramer MW, Perner S, Merseburger AS.
Oncol Lett. 2017 Jan;13(1):22-28. doi: 10.3892/ol.2016.5392. Epub 2016 Nov 17.
PMID: 28123517

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.
Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A.
Oncotarget. 2017 Apr 20. doi: 10.18632/oncotarget.17279. [Epub ahead of print]

[The Lubeck medical consultation bag].
Hupe MC, Hennig MJP, Struck JP, Salem J, Merseburger AS, Kramer MW.
Urologe A. 2017 May;56(5):662-664. doi: 10.1007/s00120-017-0372-x. German. No abstract available.

Minimally invasive approaches to adrenal tumors: an up-to-date summary including patient position and port placement of laparoscopic, retroperitoneoscopic, robot-assisted, and single-site adrenalectomy.
Hupe MC, Imkamp F, Merseburger AS.
Curr Opin Urol. 2017 Jan;27(1):56-61.

Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer.
Jordan AR, Lokeshwar SD, Lopez LE, Hennig M, Chipollini J, Yates T, Hupe MC, Merseburger AS, Shiedlin A, Cerwinka WH, Liu K, Lokeshwar VB.
Oncotarget. 2017 Apr 11;8(15):24262-24274. doi: 10.18632/oncotarget.10529.

Wann ist bei eingetretener Metastasierung des Nierenkarzinoms die operative Entfernung des Primärtumors angezeigt und gibt es eine wissenschaftliche Grundlage dafür?
Gilbert, N., Merseburger, A.S. & Kramer, M.W.
Urologe (2017) 56: 604. doi:10.1007/s00120-017-0364-x